For instance, there is evidence that ibrutinib reduces immunosuppressive PD-1 and CTLA-4 expression on T cells from chronic lymphocytic leukaemia (CLL) patients [47]. Here, CTLA4 is linked to B-cell chronic lymphocytic leukemia.